William (Bill) Mallender joined Tango Therapeutics as Vice President of Biochemistry in August 2020. Bill brings extensive experience in biochemical and biophysical assay development, enzymology, high throughput screening and pipeline governance to his role, guiding the small molecule drug discovery efforts and expanding Tango’s drug discovery portfolio. Bill joined Tango from Takeda Pharmaceuticals Portfolio Governance group for the Oncology drug discovery unit. Prior to this, Bill was a member of the Takeda Boston lead discovery group and before that the Oncology Biochemistry group. Bill joined Takeda from Millennium Pharmaceuticals’ oncology biochemistry and lead discovery groups.
Bill earned his Bachelor of Science in Microbiology from Purdue University and his Master of Science and Doctorate in Microbiology (Immunochemistry) from the University of Illinois at Urbana-Champaign. He completed his postdoctoral studies and held a junior faculty position at the Mayo Clinic Jacksonville, studying the mechanistic enzymology of acetylcholinesterase and beta-secretase for potential therapeutic inhibitor design.